Semin Respir Crit Care Med 2024; 45(01): 041-049
DOI: 10.1055/s-0043-1776757
Review Article

Pathological Diagnosis of Pulmonary Aspergillosis

Henrik E. Jensen
1   Section for Pathobiological Sciences, Division of Pathology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
,
Cecilie B. Becker
1   Section for Pathobiological Sciences, Division of Pathology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
› Institutsangaben

Abstract

Pulmonary aspergillosis constitutes an increasingly prevalent and potentially fatal complex of mycotic diseases, caused by different species of Aspergillus. The broad spectrum of pathological manifestations associated with pulmonary aspergillosis necessitates a differentiation of commensalism from saprophytic colonization, hypersensitivity reactions, and true invasive infections, which highlights the importance of histopathology as a gold standard in a diagnostic setting. For the past decades, changes in terminology and contradicting contributions from different diagnostic disciplines have made the classification of pulmonary aspergillosis rather confusing. This review offers a categorization of aspergillosis lesions based on what can be histopathologically identified and distinguished, differentiating between acute invasive infection and forms of subacute, chronic, and allergic diseases and coinfections, and summarizes important manifestations of lesions associated with the different forms of pulmonary aspergillosis.



Publikationsverlauf

Artikel online veröffentlicht:
24. Januar 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022
  • 2 Jensen HE. Aspergillosis. In: Histopathologic Diagnosis of Invasive Mycoses. CRC Press; 2023: 53-67
  • 3 De Pauw B, Walsh TJ, Donnelly JP. et al; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12) 1813-1821
  • 4 Mudrakola HV, Tandon YK, DeMartino E, Tosh PK, Yi ES, Ryu JH. Autopsy study of fatal invasive pulmonary aspergillosis: often undiagnosed premortem. Respir Med 2022; 199: 106882
  • 5 Choi S, Song JS, Kim JY. et al. Diagnostic performance of immunohistochemistry for the aspergillosis and mucormycosis. Mycoses 2019; 62 (11) 1006-1014
  • 6 Challa S, Uppin SG, Uppin MS, Pamidimukkala U, Vemu L. Diagnosis of filamentous fungi on tissue sections by immunohistochemistry using anti-aspergillus antibody. Med Mycol 2015; 53 (05) 470-476
  • 7 Son HJ, Song JS, Choi S. et al. A comparison of histomorphologic diagnosis with culture- and immunohistochemistry-based diagnosis of invasive aspergillosis and mucormycosis. Infect Dis (Lond) 2020; 52 (04) 279-283
  • 8 Shinozaki M, Okubo Y, Nakayama H. et al. Application of in situ hybridization to tissue sections for identification of molds causing invasive fungal infection. Med Mycol J 2009; 50 (02) 75-83
  • 9 Moura S, Cerqueira L, Almeida A. Invasive pulmonary aspergillosis: current diagnostic methodologies and a new molecular approach. Eur J Clin Microbiol Infect Dis 2018; 37 (08) 1393-1403
  • 10 Montone KT, LiVolsi VA, Lanza DC. et al. In situ hybridization for specific fungal organisms in acute invasive fungal rhinosinusitis. Am J Clin Pathol 2011; 135 (02) 190-199
  • 11 Challa S. Pathogenesis and pathology of invasive aspergillosis. Curr Fungal Infect Rep 2018; 12 (01) 23-32
  • 12 Gao Y, Soubani A. Advances in the diagnosis and management of pulmonary aspergillosis. Adv Respir Med 2019; 87 (06) 231-243
  • 13 Kanj A, Abdallah N, Soubani AO. The spectrum of pulmonary aspergillosis. Respir Med 2018; 141: 121-131
  • 14 Chabi ML, Goracci A, Roche N, Paugam A, Lupo A, Revel MP. Pulmonary aspergillosis. Diagn Interv Imaging 2015; 96 (05) 435-442
  • 15 Buckingham SJ, Hansell DM. Aspergillus in the lung: diverse and coincident forms. Eur Radiol 2003; 13 (08) 1786-1800
  • 16 Ben-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 2009; 114 (26) 5393-5399
  • 17 Franquet T, Müller NL, Giménez A, Guembe P, de La Torre J, Bagué S. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics 2001; 21 (04) 825-837
  • 18 Kradin RL, Mark EJ. The pathology of pulmonary disorders due to Aspergillus spp. Arch Pathol Lab Med 2008; 132 (04) 606-614
  • 19 Moldoveanu B, Gearhart AM, Jalil BA, Saad M, Guardiola JJ. Pulmonary aspergillosis: spectrum of disease. Am J Med Sci 2021; 361 (04) 411-419
  • 20 Barac A, Vukicevic TA, Ilic AD, Rubino S, Zugic V, Stevanovic G. Complications of chronic necrotizing pulmonary aspergillosis: review of published case reports. Rev Inst Med Trop São Paulo 2017; 59: e19
  • 21 Tochigi N, Okubo Y, Ando T. et al. Histopathological implications of Aspergillus infection in lung. Mediators Inflamm 2013; 2013: 809798
  • 22 Anantasit N, Nuntacharruksa N, Incharoen P, Preutthipan A. Clinical and pathological correlation in pediatric invasive pulmonary aspergillosis. Front Pediatr 2018; 6: 31
  • 23 Douglas AP, Smibert OC, Bajel A. et al; Australasian Antifungal Guidelines Steering Committee. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J 2021; 51 (Suppl. 07) 143-176
  • 24 Denning DW, Cadranel J, Beigelman-Aubry C. et al; European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016; 47 (01) 45-68
  • 25 Muldoon EG, Sharman A, Page I, Bishop P, Denning DW. Aspergillus nodules; another presentation of chronic pulmonary aspergillosis. BMC Pulm Med 2016; 16 (01) 123
  • 26 Chacko A, Moss RB. Manifestations of pulmonary aspergillosis in pediatrics. Curr Opin Pediatr 2020; 32 (03) 389-394
  • 27 Takazono T, Izumikawa K. Recent advances in diagnosing chronic pulmonary aspergillosis. Front Microbiol 2018; 9: 1810
  • 28 Larkin PMK, Multani A, Beaird OE, Dayo AJ, Fishbein GA, Yang S. A collaborative tale of diagnosing and treating chronic pulmonary aspergillosis, from the perspectives of clinical microbiologists, surgical pathologists, and infectious disease clinicians. J Fungi (Basel) 2020; 6 (03) e1-e27
  • 29 Schweer KE, Bangard C, Hekmat K, Cornely OA. Chronic pulmonary aspergillosis. Mycoses 2014; 57 (05) 257-270
  • 30 Tashiro T, Izumikawa K, Tashiro M. et al. A case series of chronic necrotizing pulmonary aspergillosis and a new proposal. Jpn J Infect Dis 2013; 66 (04) 312-316
  • 31 Izumikawa K, Tashiro T, Tashiro M. et al. Pathogenesis and clinical features of chronic pulmonary aspergillosis - is it possible to distinguish CNPA and CCPA clinically?. J Infect Chemother 2014; 20 (03) 208-212
  • 32 Hayes GE, Novak-Frazer L. Chronic pulmonary aspergillosis—where are we? And where are we going?. J Fungi (Basel) 2016; 2 (02) e1-e34
  • 33 Feng X, Yao Z, Liao W. Progress in the diagnosis and treatment of pulmonary aspergillosis. Curr Respir Med Rev 2012; 8: 346-355
  • 34 Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 (Suppl. 03) S265-S280
  • 35 Kosmidis C, Newton P, Muldoon EG, Denning DW. Chronic fibrosing pulmonary aspergillosis: a cause of 'destroyed lung' syndrome. Infect Dis (Lond) 2017; 49 (04) 296-301
  • 36 Pendleton M, Denning DW. Multifocal pulmonary aspergillomas: case series and review. Ann N Y Acad Sci 2012; 1272 (01) 58-67
  • 37 Tochigi N, Ishiwatari T, Okubo Y. et al. Histological study of chronic pulmonary aspergillosis. Diagn Pathol 2015; 10 (01) 153
  • 38 Maheshwari V, Varshney M, Alam K. et al. Aspergilloma lung mimicking tuberculosis. BMJ Case Rep 2011; 2011: 2-5
  • 39 Limaiem F, Blibech H, Bouhajja L, Ben Farhat L, Louzir B. Pulmonary aspergilloma with prominent oxalate deposition. Clin Case Rep 2022; 10 (11) e6667
  • 40 Ito Y, Tanigawa M, Takemura T. et al. Chronic nodular pulmonary aspergillosis in a patient with rheumatoid arthritis. Intern Med 2019; 58 (07) 979-984
  • 41 Kang N, Park J, Jhun BW. Clinical characteristics and treatment outcomes of pathologically confirmed Aspergillus nodules. J Clin Med 2020; 9 (07) e1-e10
  • 42 Dabó H, Marinho A, Gomes I. Pulmonary Aspergillus nodule - still challenging?. BMC Pulm Med 2016; 16: 123
  • 43 Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) 1970; 49 (02) 147-173
  • 44 Brandt C, Roehmel J, Rickerts V, Melichar V, Niemann N, Schwarz C. Aspergillus bronchitis in patients with cystic fibrosis. Mycopathologia 2018; 183 (01) 61-69
  • 45 Chrdle A, Mustakim S, Bright-Thomas RJ, Baxter CG, Felton T, Denning DW. Aspergillus bronchitis without significant immunocompromise. Ann N Y Acad Sci 2012; 1272 (01) 73-85
  • 46 Symmers WC. Histopathologic aspects of the pathogenesis of some opportunistic fungal infections, as exemplified in the pathology of aspergillosis and the phycomycetoses. Lab Invest 1962; 11 (11) 1073-1090
  • 47 Asano K, Kamei K, Hebisawa A. Allergic bronchopulmonary mycosis - pathophysiology, histology, diagnosis, and treatment. Asia Pac Allergy 2018; 8 (03) e24
  • 48 McCarthy MW, Aguilar-Zapata D, Petraitis V, Walsh TJ. Diagnosis, classification, and therapeutic interventions for sinopulmonary Aspergillosis. Expert Rev Respir Med 2017; 11 (03) 229-238
  • 49 Wark P. Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment. Respir Med 2004; 98 (10) 915-923
  • 50 Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 2005; 60 (08) 1004-1013
  • 51 Chetty A. Pathology of allergic bronchopulmonary aspergillosis. Front Biosci 2003; 8: e110-e114
  • 52 Bosken CH, Myers JL, Greenberger PA, Katzenstein A-LA. Pathologic features of allergic bronchopulmonary aspergillosis. Am J Surg Pathol 1988; 12 (03) 216-222
  • 53 Denning DW, Chakrabarti A. Pulmonary and sinus fungal diseases in non-immunocompromised patients. Lancet Infect Dis 2017; 17 (11) e357-e366
  • 54 Raghu G, Remy-Jardin M, Ryerson CJ. et al. Diagnosis of hypersensitivity pneumonitis in adults: an official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2020; 202 (03) e36-e69
  • 55 Takemura T, Akashi T, Ohtani Y, Inase N, Yoshizawa Y. Pathology of hypersensitivity pneumonitis. Curr Opin Pulm Med 2008; 14 (05) 440-454
  • 56 Churg A, Bilawich A, Wright JL. Pathology of chronic hypersensitivity pneumonitis: what is it? What are the diagnostic criteria? Why do we care?. Arch Pathol Lab Med 2018; 142 (01) 109-119
  • 57 Walsh SLF, Wells AU, Desai SR. et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med 2016; 4 (07) 557-565
  • 58 Barrios RJ. Hypersensitivity pneumonitis: histopathology. Arch Pathol Lab Med 2008; 132 (02) 199-203
  • 59 Feys S, Almyroudi MP, Braspenning R. et al. A visual and comprehensive review on COVID-19-associated pulmonary aspergillosis (CAPA). J Fungi (Basel) 2021; 7 (12) e1-e20
  • 60 Robinson KM. Mechanistic basis of super-infection: influenza-associated invasive pulmonary aspergillosis. J Fungi (Basel) 2022; 8 (05) e1-e7
  • 61 Reizine F, Pinceaux K, Lederlin M. et al. Influenza-and covid-19-associated pulmonary aspergillosis: are the pictures different?. J Fungi (Basel) 2021; 7 (05) e1-e13
  • 62 Koehler P, Bassetti M, Chakrabarti A. et al; European Confederation of Medical Mycology, International Society for Human Animal Mycology, Asia Fungal Working Group, INFOCUS LATAM/ISHAM Working Group, ISHAM Pan Africa Mycology Working Group, European Society for Clinical Microbiology, Infectious Diseases Fungal Infection Study Group, ESCMID Study Group for Infections in Critically Ill Patients, Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy, Medical Mycology Society of Nigeria, Medical Mycology Society of China Medicine Education Association, Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology, Association of Medical Microbiology, Infectious Disease Canada. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021; 21 (06) e149-e162
  • 63 Marr KA, Platt A, Tornheim JA. et al. Aspergillosis complicating severe coronavirus disease. Emerg Infect Dis 2021; 27 (01) 18-25
  • 64 Feys S, Gonçalves SM, Khan M. et al. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study. Lancet Respir Med 2022; 10 (12) 1147-1159
  • 65 van de Veerdonk FL, Brüggemann RJM, Vos S. et al. COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. Lancet Respir Med 2021; 9 (07) 795-802
  • 66 Fortarezza F, Boscolo A, Pezzuto F. et al. Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure. Mycoses 2021; 64 (10) 1223-1229
  • 67 Casalini G, Giacomelli A, Galimberti L. et al. Challenges in diagnosing COVID-19-associated pulmonary aspergillosis in critically ill patients: the relationship between case definitions and autoptic data. J Fungi (Basel) 2022; 8 (09) e1-e16